Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

Clinical Breast Cancer
Joyce O'shaughnessyJohn E Pippen

Abstract

We evaluated the efficacy and toxicity of trastuzumab plus gemcitabine in patients with HER2-positive metastatic breast cancer (MBC). Sixty-four patients were enrolled, the majority of whom (95%) had been treated with an anthracycline and a taxane before study enrollment. Eligible women were treated with gemcitabine (1200 mg/m(2) weekly for 2 weeks with the third week off on a 21-day cycle) plus weekly doses of trastuzumab (4-mg/kg loading dose; 2 mg/kg thereafter) until disease progression. The median patient age was 55 years, and the median number of previously administered (including adjuvant) chemotherapy regimens was 3. Twenty-two patients were scored as 2+ for HER2 expression by immunohistochemistry; 39 patients scored 3+. Three patients were assessed as HER2-negative on central pathology review and were ineligible for evaluation. Fifty-nine of the 61 patients remained evaluable for response. The objective response rates were 38% in the intent-to-treat population (23 of 61) and 44% among the 39 patients with HER2 3+ expression. The median response duration was 5.8 months, median overall survival was 14.7 months, and median time to disease progression was 5.8 months. Trastuzumab plus gemcitabine was well tolerated. No case...Continue Reading

Citations

Jul 20, 2006·International Journal of Clinical Oncology·Eriko TokunagaYoshihiko Maehara
Dec 25, 2008·Nature Clinical Practice. Oncology·Gabriella MarianiLuca Gianni
Sep 22, 2007·Drugs·Michael F Press, Heinz-Josef Lenz
Sep 1, 2005·Women's Health·Ian E Smith, Susan G Cross
Apr 21, 2012·Clinical Medicine Insights. Oncology·Alwin Jeyakumar, Tallal Younis
Jun 1, 2008·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hye Jin KimYung-Jue Bang
Oct 8, 2016·British Journal of Pharmacology·Balazs T NemethPal Pacher
Jun 19, 2017·Journal of Cancer Research and Clinical Oncology·Mukundan Baskar Mannargudi, Subrata Deb
Feb 8, 2006·American Journal of Clinical Oncology·Alberto OcañaAtanasio Pandiella
Sep 23, 2008·Expert Opinion on Pharmacotherapy·Giulio MetroAlessandra Fabi
Apr 9, 2009·Expert Opinion on Pharmacotherapy·Patrick G MorrisClifford A Hudis
Jan 1, 2009·Immunity & Ageing : I & a·Biagio AgostaraAntonella Usset
May 29, 2007·Breast Cancer Research and Treatment·Susan DentMaureen Trudeau
Feb 8, 2008·Cancer Chemotherapy and Pharmacology·Rupert BartschGuenther G Steger
Jul 25, 2012·Anti-cancer Drugs·Conleth G Murphy, Patrick G Morris
Feb 10, 2012·Expert Review of Anticancer Therapy·Carole GourmelonMario Campone
Jul 13, 2006·Expert Review of Anticancer Therapy·Niklaus G SchaeferChristoph Renner
Feb 24, 2010·Expert Opinion on Drug Safety·A Jo Chien, Hope S Rugo
Sep 25, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Richard L SchroederJayalakshmi Sridhar
Jun 15, 2005·Expert Opinion on Biological Therapy·S RueckertM Untch
Jun 22, 2005·World Journal of Gastroenterology : WJG·Xiao-Ping LiJie Li
May 19, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Alberto OcañaJuan J Cruz
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Zhen-Li ZhuKe Li
Jul 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BeslijaH Zwierzina
Aug 21, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V HeinemannH J Stemmler
Dec 2, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C A HarrisS Pearson
Jan 16, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Gaston DemontyMartine Piccart
Jan 26, 2010·Critical Reviews in Oncology/hematology·Claudia AndreettaFabio Puglisi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.